On February 5, 2019 Bolt Biotherapeutics, Inc., a biotechnology company focused on unleashing the power of the immune system to achieve anti-tumor immunity in patients, reported the completion of a $54M Series B financing led by Pivotal bioVenture Partners with additional participation from Nan Fung Life Sciences (Press release, Bolt Biotherapeutics, FEB 5, 2019, View Source [SID1234533829]). Existing investors Novo Holdings and Vivo Capital also participated in the financing. The funds will be used to advance the company’s lead Boltbody Immune-Stimulating Antibody Conjugate (ISAC) into the clinic as well as to build the company’s pipeline and further develop its technology platform.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We have made significant progress with our Boltbody ISAC platform that harnesses the ability of toll-like receptor (TLR) agonists to convert cold tumors into immunologically hot tumors following systemic administration. We are well positioned to bring this novel technology into clinical development and look forward to sharing more about our lead program, pipeline and platform in the months ahead," stated Peter Moldt, Ph.D., of Novo Ventures and executive chairman of the board of Bolt Biotherapeutics. "We are pleased that this group of world-class biotech investors has chosen to join us on this important mission of developing a unique class of cancer immunotherapies."
"The rapid development of Bolt’s promising targeted therapeutic platform has been very impressive," noted Ash Khanna, Ph.D., venture partner at Pivotal bioVenture Partners. "Bolt’s proprietary ISAC technology is differentiated from other immuno-oncology approaches as evidenced by the strength of the preclinical safety and efficacy data, including durable systemic anti-tumor immunity and I look forward to working with the experienced team and investors to advance the company’s programs into the clinic."